Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

Bradley A. Carlson, M M Dubay, Edward A. Sausville et al. · PubMed · 1996 · 537 citations

Medicine, Oncology, Pharmacology +14

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

Walter Filgueira de Azevedo, H J Mueller-Dieckmann, Ursula Schulze‐Gahmen et al. · Proceedings of the National Academy of Sciences · 1996 · 500 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

Adrian M. Senderowicz, Donna Headlee, Sherman F. Stinson et al. · Journal of Clinical Oncology · 1998 · 408 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +15

Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275

Gurmeet Kaur, M Stetler-Stevenson, S Sebers et al. · JNCI Journal of the National Cancer Institute · 1992 · 351 citations

Medicine, Oncology, Pharmacology +13

Potent Inhibition of Cdc2 Kinase Activity by the Flavonoid L86-8275

Michael D. Losiewicz, B. A. Carlson, Gurmeet Kaur et al. · Biochemical and Biophysical Research Communications · 1994 · 346 citations

Life Sciences, Cell Biology, Pharmacology +15